BLCO's revenue growth has re-accelerated to 7.3% in 2026Q3 and gross margin has expanded from 51.7% in 2025Q1 to 60.5%, suggesting improving unit economics and a sustained operating recovery with operating margin reaching 11.3%.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 7.3% and operating margin improved from -5.4% in 2025Q1 to 11.3% in 2026Q3, yet net margin of 2.3% and a 21% operating-to-net income conversion ratio suggest significant below-the-line drag persists.
Bausch + Lomb delivered a solid 9% YoY revenue growth to $1.24B in Q1 2026, indicating robust business performance.
Adjusted EBITDA Excluding Acquired IPR&D surged 59% YoY to $200M, showcasing significant operational leverage.
The company demonstrated that promised FY25 structural margin improvements are flowing to the bottom line in Q1 2026.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | $0.34+58.5% vs $0.21 | $1.4B+0.2% vs $1.4B |
Q3 2026 Jul 29, 2026 | $0.16+3.6% vs $0.15 | $1.4B+1.8% vs $1.4B |
Q2 2026 Apr 29, 2026 | $0.08+33.3% vs $0.06 | $1.2B+2.3% vs $1.2B |
Q1 2026 Feb 18, 2026 | $0.32-8.6% vs $0.35 | $1.4B+1.4% vs $1.4B |
Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report)'s stock price fell 5.8% during mid-day trading on Monday. The company traded as low as $16.13 and last traded at $16.2990. Approximately 154,963 shares traded hands during trading, a decline of 63% from the average daily volume of 414,952 shares. The stock had previously closed at
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Dir.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA). The discussion provided greater clarity on the clinical development path for BL1243. If successf.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the c.
Benchmark BLCO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bausch + Lomb Corporation (BLCO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.99 | $7.14B | -65.09 | 6.47% | -2.05% | -1.71% | — | |
| $86.05 | $9.8B | 23.00 | 4.03% | 3.07% | 8.83% | — | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — | |
| $100.61 | $6.55B | 25.50 | 0.5% | 17.28% | 21.72% | — | |
| $276.22 | $664.92B | 42.02 | 6.05% | 16.2% | 19.55% | 1.85% | |
| $109.93 | $191.48B | 40.64 | 5.67% | 9.75% | 9% | 2.14% |
Bausch + Lomb Corporation (BLCO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bausch + Lomb Corporation (BLCO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Oct 28, 2026·SEC
Oct 13, 2026·SEC
Get notified when BLCO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bausch + Lomb Corporation (BLCO) stock FAQ — growth, dividends, profitability & financials explained
Bausch + Lomb Corporation (BLCO) reported $5.41B in revenue over the trailing twelve months. Revenue was $5.10B in fiscal year 2025. That is 35% more than the $3.78B of fiscal year 2019.
Bausch + Lomb Corporation (BLCO) grew revenue by 8.8% over the trailing twelve months, compared with the twelve months before.
No. Bausch + Lomb Corporation (BLCO) reported a net loss of $111.0M over the trailing twelve months.
Bausch + Lomb Corporation (BLCO) had a return on equity (ROE) of -1.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Bausch + Lomb Corporation (BLCO) generated $253.8M in free cash flow over the trailing twelve months.
